<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470429</url>
  </required_header>
  <id_info>
    <org_study_id>EXK947-P001</org_study_id>
    <nct_id>NCT02470429</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION</brief_title>
  <official_title>Evaluation of Clinical Outcomes Following the Use of SYSTANE® HYDRATION in Subjects With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare SYSTANE® HYDRATION to Hyabak 0.15% based on total
      ocular surface staining scores (TOSS) at Day 42.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will first be dispensed preservative-free 0.9% saline eye drops (saline eye drops)
      to be used during the Run-in phase between Screening Visit and Day 0 (Visit 1). Subjects who
      qualify will be randomized in a 1:1 manner to receive either treatment with SYSTANE®
      HYDRATION Lubricant Eye Drops or Hyabak 0.15% Eye Drops.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2015</start_date>
  <completion_date type="Actual">May 26, 2016</completion_date>
  <primary_completion_date type="Actual">May 26, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 42</measure>
    <time_frame>Baseline (Day 0), Day 42</time_frame>
    <description>The TOSS score is a cumulative cornea and conjunctival staining score. After instilling ophthalmic dye in the eye, the investigator graded 3 areas of the ocular surface for dryness on a scale from 0 to 5, where 0=Absent and 5=Severe. The 3 scores were summed for a resultant overall 0-15 score. A more negative change value indicates greater efficacy. One eye (study eye) contributed to the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IDEEL Treatment Effectiveness Score at Day 42</measure>
    <time_frame>Baseline (Day 0), Day 42</time_frame>
    <description>The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IDEEL Treatment Inconvenience Score at Day 42</measure>
    <time_frame>Baseline (Day 0), Day 42</time_frame>
    <description>The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tear Film Break-up Time (TFBUT) at Day 42</measure>
    <time_frame>Baseline (Day 0), Day 42</time_frame>
    <description>TFBUT is defined as the time elapsed from the last blink until 1 or more dry spots appeared in the precorneal tear film. A longer tear film break-up time indicates a more stable tear film and may lead to improvement in dry eye symptoms. One eye (study eye) contributed to the analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>SYSTANE HYDRATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyabak 0.15%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYSTANE HYDRATION lubricant eye drops</intervention_name>
    <description>Preserved with POLYQUAD (polidronium chloride) 0.001%</description>
    <arm_group_label>SYSTANE HYDRATION</arm_group_label>
    <other_name>SYSTANE® HYDRATION</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyabak 0.15% eye drops</intervention_name>
    <description>Preservative-free</description>
    <arm_group_label>Hyabak 0.15%</arm_group_label>
    <other_name>Hyabak 0.15%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% saline eye drops</intervention_name>
    <description>Preservative-free, one drop 4 times a day in each eye (run-in period)</description>
    <arm_group_label>SYSTANE HYDRATION</arm_group_label>
    <arm_group_label>Hyabak 0.15%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to attend all study visits;

          -  Use of non-BAK (Benzalkonium Chloride) artificial tears at least once a day, for at
             least 3 months prior to Screening Visit;

          -  Diagnosis of Dry Eye (by a health care professional) for at least 3 months prior to
             Screening Visit;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential who are pregnant or breast feeding;

          -  Any hypersensitivity to the use of the study products or an allergy to any
             ingredient(s) contained within study products;

          -  Ocular abnormalities in either eye that could adversely affect the safety or efficacy
             outcome;

          -  Active ocular infection (bacterial, viral, or fungal) or active inflammation not
             associated with dry eye;

          -  Use of chronic systemic medications: (prescription, over the counter,
             vitamins/supplements) on a stable dose for less than 30 days prior to Screening Visit,
             or any anticipated change in dosing regimen during the course of the study;

          -  History of ocular or intraocular surgery or serious ocular trauma in either eye within
             6 months prior to Screening Visit;

          -  Any medical condition (systemic or ophthalmic) that may, in the opinion of the
             Investigator, preclude the safe administration of study products or safe participation
             in the study;

          -  Use of any topical ocular over-the-counter or prescribed medications in either eye
             (with the exception of artificial tears/gels/ lubricants) 2 weeks prior to Screening
             Visit;

          -  Contact lens use within 2 weeks prior to Screening Visit and unwilling to avoid
             contact lens use during the course of the study;

          -  Unwilling to avoid the use of additional artificial tears (other than the study
             products) throughout the study;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Trial Leader, Global Development Operations</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <results_first_submitted>April 4, 2017</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2017</results_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 3 study centers located in Germany, 3 study centers located in France, 2 study centers located in the UK, and 2 study centers located in Spain.</recruitment_details>
      <pre_assignment_details>Of the 114 enrolled, 15 subjects were exited as screen failures prior to randomization. This reporting group includes all randomized subjects (99).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SYSTANE HYDRATION</title>
          <description>SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
        </group>
        <group group_id="P2">
          <title>Hyabak 0.15%</title>
          <description>Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all subjects who were exposed to study drug (including the run-in therapy) (Safety Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>SYSTANE HYDRATION</title>
          <description>SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
        </group>
        <group group_id="B2">
          <title>Hyabak 0.15%</title>
          <description>Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="12.29"/>
                    <measurement group_id="B2" value="56.7" spread="14.29"/>
                    <measurement group_id="B3" value="59.2" spread="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Ocular Surface Staining (TOSS) Score</title>
          <description>The TOSS score is a cumulative cornea and conjunctival staining score. After instilling ophthalmic dye in the eye, the investigator graded 3 areas of the ocular surface for dryness on a scale from 0 to 5, where 0=Absent and 5=Severe. The 3 scores were summed for a resultant overall 0-15 score.</description>
          <population>This analysis population includes all subjects who received at least 1 dose of the randomized study drug (Intent-to-Treat (ITT) Analysis Set).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.26" spread="1.411"/>
                    <measurement group_id="B2" value="4.98" spread="1.090"/>
                    <measurement group_id="B3" value="5.12" spread="1.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IDEEL Treatment Score</title>
          <description>The IDEEL (Impact of dry eye on everyday life) is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use (Treatment Effectiveness and Treatment Inconvenience). A resultant overall 0-100 treatment satisfaction score was calculated separately for Treatment Effectiveness and Treatment Inconvenience, with higher scores indicating greater satisfaction and less treatment-related bother.</description>
          <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Treatment Effectiveness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.04" spread="29.602"/>
                    <measurement group_id="B2" value="51.56" spread="28.641"/>
                    <measurement group_id="B3" value="51.80" spread="28.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Inconvenience</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.42" spread="17.749"/>
                    <measurement group_id="B2" value="81.90" spread="17.829"/>
                    <measurement group_id="B3" value="82.67" spread="17.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tear Film Break-up Time (TFBUT)</title>
          <description>TFBUT is defined as the time elapsed from the last blink until 1 or more dry spots appeared in the precorneal tear film.</description>
          <population>ITT Analysis Set.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.20" spread="2.010"/>
                    <measurement group_id="B2" value="3.58" spread="2.222"/>
                    <measurement group_id="B3" value="3.39" spread="2.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 42</title>
        <description>The TOSS score is a cumulative cornea and conjunctival staining score. After instilling ophthalmic dye in the eye, the investigator graded 3 areas of the ocular surface for dryness on a scale from 0 to 5, where 0=Absent and 5=Severe. The 3 scores were summed for a resultant overall 0-15 score. A more negative change value indicates greater efficacy. One eye (study eye) contributed to the analysis.</description>
        <time_frame>Baseline (Day 0), Day 42</time_frame>
        <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
        <group_list>
          <group group_id="O1">
            <title>SYSTANE HYDRATION</title>
            <description>SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
          <group group_id="O2">
            <title>Hyabak 0.15%</title>
            <description>Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 42</title>
          <description>The TOSS score is a cumulative cornea and conjunctival staining score. After instilling ophthalmic dye in the eye, the investigator graded 3 areas of the ocular surface for dryness on a scale from 0 to 5, where 0=Absent and 5=Severe. The 3 scores were summed for a resultant overall 0-15 score. A more negative change value indicates greater efficacy. One eye (study eye) contributed to the analysis.</description>
          <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="0.24"/>
                    <measurement group_id="O2" value="-0.92" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IDEEL Treatment Effectiveness Score at Day 42</title>
        <description>The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.</description>
        <time_frame>Baseline (Day 0), Day 42</time_frame>
        <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
        <group_list>
          <group group_id="O1">
            <title>SYSTANE HYDRATION</title>
            <description>SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
          <group group_id="O2">
            <title>Hyabak 0.15%</title>
            <description>Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IDEEL Treatment Effectiveness Score at Day 42</title>
          <description>The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.</description>
          <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.62" spread="3.19"/>
                    <measurement group_id="O2" value="12.80" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IDEEL Treatment Inconvenience Score at Day 42</title>
        <description>The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.</description>
        <time_frame>Baseline (Day 0), Day 42</time_frame>
        <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
        <group_list>
          <group group_id="O1">
            <title>SYSTANE HYDRATION</title>
            <description>SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
          <group group_id="O2">
            <title>Hyabak 0.15%</title>
            <description>Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IDEEL Treatment Inconvenience Score at Day 42</title>
          <description>The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.</description>
          <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.32" spread="2.22"/>
                    <measurement group_id="O2" value="2.24" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tear Film Break-up Time (TFBUT) at Day 42</title>
        <description>TFBUT is defined as the time elapsed from the last blink until 1 or more dry spots appeared in the precorneal tear film. A longer tear film break-up time indicates a more stable tear film and may lead to improvement in dry eye symptoms. One eye (study eye) contributed to the analysis.</description>
        <time_frame>Baseline (Day 0), Day 42</time_frame>
        <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
        <group_list>
          <group group_id="O1">
            <title>SYSTANE HYDRATION</title>
            <description>SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
          <group group_id="O2">
            <title>Hyabak 0.15%</title>
            <description>Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tear Film Break-up Time (TFBUT) at Day 42</title>
          <description>TFBUT is defined as the time elapsed from the last blink until 1 or more dry spots appeared in the precorneal tear film. A longer tear film break-up time indicates a more stable tear film and may lead to improvement in dry eye symptoms. One eye (study eye) contributed to the analysis.</description>
          <population>ITT Analysis Set. Number Analyzed is the number of subjects with non-missing response.</population>
          <units>seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.38"/>
                    <measurement group_id="O2" value="0.68" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from time of consent for the duration of a subject’s participation in the study (up to 63 days). AEs are reported as pretreatment and treatment-emergent.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a subject who was administered an investigational product regardless of whether or not the event had a causal relationship with the treatment. AEs were obtained through volunteered and elicited comments from subjects and through observations by the Investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pretreatment</title>
          <description>All subjects who consented to participate in the study prior to the initiation of study treatment</description>
        </group>
        <group group_id="E2">
          <title>SYSTANE HYDRATION</title>
          <description>All subjects treated with SYSTANE HYDRATION lubricant eye drops</description>
        </group>
        <group group_id="E3">
          <title>Hyabak 0.15%</title>
          <description>All subjects treated with Hyabak 0.15% eye drops</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>WW Medical Affairs Director, GMA Ophthalmics</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

